Streetbeat News

Equity Actions

PRVA

Privia Health Gr (NASDAQ:PRVA) has been evaluated by 4 analysts over the last three months, showing a mix of bullish to indifferent sentiments. The average 12-month price target is now $25.25, a decrease from the previous $28.33. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Privia Health Gr, a technology-driven physician-enablement company, shows strong net margin and ROE but lags in revenue growth and ROA compared to industry peers. Its market capitalization and debt management indicate a smaller scale and conservative financial approach.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:01 pm

GPOR

Gulfport Energy (NYSE:GPOR) has received mixed analyst ratings over the last three months, with a recent shift towards a more bullish outlook. The average 12-month price target for GPOR has been raised to $154.6, indicating a slight increase from the previous target. Financial analysis reveals challenges in revenue growth and market capitalization but highlights strong profitability metrics such as net margin, ROE, and ROA. GPOR's debt management is also noted positively.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:00 pm

RLJ

RLJ Lodging (NYSE:RLJ) has been analyzed by 5 analysts, showing a mix of bullish to indifferent sentiments. Recent ratings reveal an average 12-month price target of $14.1, marking a 10.59% increase from the previous target. Analysts from Oppenheimer, Wolfe Research, Truist Securities, and Wells Fargo have adjusted their ratings and price targets, reflecting optimism. Despite this, RLJ faces revenue challenges, with a -4.4% growth over 3 months, and struggles in profitability and asset utilization, indicated by low net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:00 pm

BKKT

ICE

Bakkt Holdings Inc (NYSE:BKKT) shares fell 34% to $0.67 after announcing two securities purchase agreements. The first involves selling 46,136,102 shares at $0.8670 per share to institutional investors, and the second, a sale of up to 11,534,025 shares at the same price to an affiliate of Intercontinental Exchange, Inc. (ICE). The offerings are expected to generate approximately $42.4 million for working capital and general corporate purposes. Bakkt operates a platform for Bitcoin and other digital assets.

Portfolio Pulse from Henry Khederian

February 29, 2024 | 4:18 pm

PRST

Presto Automation Inc (NASDAQ:PRST) shares dropped 24% to $0.30 after announcing a securities purchase agreement to sell 8,533,000 shares at $0.25 each. The offering, managed by Chardan and Spartan as joint placement agents, aims to raise approximately $2.1 million for working capital and general corporate purposes, with a closing date around March 4.

Portfolio Pulse from Henry Khederian

February 29, 2024 | 4:17 pm

GDRX

GoodRx Holdings, Inc. (NASDAQ:GDRX) shares surged after reporting Q4 FY23 results with revenue and adjusted revenue up 7% Y/Y to $196.6 million, surpassing estimates. Prescription transactions revenue increased 11% to $143.9 million, driven by an 8% rise in Monthly Active Consumers. Adjusted EBITDA and EPS also beat expectations. The company announced a new stock repurchase program worth $450 million and provided FY24 revenue guidance above consensus.

Portfolio Pulse from Lekha Gupta

February 29, 2024 | 4:16 pm

VKTX

Viking Therapeutics announced the pricing of its public offering of 6,471,000 common shares at $85 per share, leading to a decrease in its stock price.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 4:02 pm

MRSN

Mersana Therapeutics (NASDAQ:MRSN) received mixed ratings from 5 analysts, with a notable upward trend in the 12-month price target to $6.6, reflecting a 103.08% increase from the previous target of $3.25. Analysts' actions include raises and maintains, with price targets ranging from $5.00 to $9.00. The company's financial performance shows substantial revenue growth and efficient cost management, despite challenges in ROE, ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 4:00 pm

MSFT

NOW

ServiceNow (NYSE:NOW) is evaluated against its competitors in the Software industry, revealing it trades at a premium with high PE, PB, and PS ratios but shows potential inefficiencies with lower ROE, EBITDA, and gross profit. Despite this, ServiceNow exhibits strong revenue growth and a favorable debt-to-equity ratio compared to its peers, including Microsoft Corp (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL), Palo Alto Networks Inc (NYSE:PANW), Gen Digital Inc (NASDAQ:GEN), Dolby Laboratories Inc (NYSE:DLB), Qualys Inc (NASDAQ:QLYS), Teradata Corp (NYSE:TDC), N-able Inc (NYSE:NABL), and Progress Software Corp (NASDAQ:PRGS).

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 4:00 pm

MA

The analysis compares Mastercard (MA) against its competitors in the Financial Services industry, highlighting its position based on key financial metrics. Mastercard shows potential undervaluation based on its PE ratio, high profitability and operational efficiency with its ROE, EBITDA, and gross profit standing out. However, concerns arise from its low revenue growth rate and high PB and PS ratios, suggesting overvaluation in terms of book value and sales performance.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 4:00 pm